Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models.
Morimura O, Minami T, Kijima T, Koyama S, Otsuka T, Kinehara Y, Osa A, Higashiguchi M, Miyake K, Nagatomo I, Hirata H, Iwahori K, Takimoto T, Takeda Y, Kida H, Kumanogoh A. Morimura O, et al. Among authors: higashiguchi m. Biochem Biophys Res Commun. 2017 Jul 8;488(4):596-602. doi: 10.1016/j.bbrc.2017.05.090. Epub 2017 May 17. Biochem Biophys Res Commun. 2017. PMID: 28526406
Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis.
Minami T, Kijima T, Kohmo S, Arase H, Otani Y, Nagatomo I, Takahashi R, Miyake K, Higashiguchi M, Morimura O, Ihara S, Tsujino K, Hirata H, Inoue K, Takeda Y, Kida H, Tachibana I, Kumanogoh A. Minami T, et al. Among authors: higashiguchi m. Sci Rep. 2013;3:2669. doi: 10.1038/srep02669. Sci Rep. 2013. PMID: 24036898 Free PMC article.
Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer.
Kinehara Y, Minami T, Kijima T, Hoshino S, Morimura O, Otsuka T, Hayama Y, Fukushima K, Takeuchi Y, Higashiguchi M, Miyake K, Hirata H, Nagatomo I, Inoue K, Takeda Y, Kida H, Kumanogoh A. Kinehara Y, et al. Among authors: higashiguchi m. Lung Cancer. 2015 Mar;87(3):321-5. doi: 10.1016/j.lungcan.2015.01.003. Epub 2015 Jan 10. Lung Cancer. 2015. PMID: 25601188
Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells.
Kinehara Y, Nagatomo I, Koyama S, Ito D, Nojima S, Kurebayashi R, Nakanishi Y, Suga Y, Nishijima-Futami Y, Osa A, Nakatani T, Kato Y, Nishide M, Hayama Y, Higashiguchi M, Morimura O, Miyake K, Kang S, Minami T, Hirata H, Iwahori K, Takimoto T, Takamatsu H, Takeda Y, Hosen N, Hoshino S, Shintani Y, Okumura M, Kumagai T, Nishino K, Imamura F, Nakatsuka SI, Kijima T, Kida H, Kumanogoh A. Kinehara Y, et al. Among authors: higashiguchi m. JCI Insight. 2018 Dec 20;3(24):e123093. doi: 10.1172/jci.insight.123093. JCI Insight. 2018. PMID: 30568033 Free PMC article.
Dapsone hypersensitivity syndrome-related lung injury without eosinophilia in the bronchoalveolar lavage fluid.
Kinehara Y, Kijima T, Inoue K, Hirata H, Takeuchi Y, Fukushima K, Hayama Y, Higashiguchi M, Morimura O, Miyake K, Minami T, Nagatomo I, Takeda Y, Kida H, Kumanogoh A. Kinehara Y, et al. Among authors: higashiguchi m. Intern Med. 2015;54(7):827-31. doi: 10.2169/internalmedicine.54.3406. Epub 2015 Apr 1. Intern Med. 2015. PMID: 25832951 Free article.
Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer.
Nishijima-Futami Y, Minami S, Futami S, Koba T, Higashiguchi M, Tamiya M, Suzuki H, Hirashima T, Komuta K, Kijima T. Nishijima-Futami Y, et al. Among authors: higashiguchi m. Cancer Chemother Pharmacol. 2017 Jun;79(6):1215-1220. doi: 10.1007/s00280-017-3321-x. Epub 2017 Apr 28. Cancer Chemother Pharmacol. 2017. PMID: 28455584 Clinical Trial.
Double deletion of tetraspanins CD9 and CD81 in mice leads to a syndrome resembling accelerated aging.
Jin Y, Takeda Y, Kondo Y, Tripathi LP, Kang S, Takeshita H, Kuhara H, Maeda Y, Higashiguchi M, Miyake K, Morimura O, Koba T, Hayama Y, Koyama S, Nakanishi K, Iwasaki T, Tetsumoto S, Tsujino K, Kuroyama M, Iwahori K, Hirata H, Takimoto T, Suzuki M, Nagatomo I, Sugimoto K, Fujii Y, Kida H, Mizuguchi K, Ito M, Kijima T, Rakugi H, Mekada E, Tachibana I, Kumanogoh A. Jin Y, et al. Among authors: higashiguchi m. Sci Rep. 2018 Mar 23;8(1):5145. doi: 10.1038/s41598-018-23338-x. Sci Rep. 2018. PMID: 29572511 Free PMC article.
Long-term amrubicin chemotherapy for small-cell lung cancer.
Higashiguchi M, Suzuki H, Hirashima T, Kobayashi M, Goya S, Okamoto N, Matsuura Y, Tamiya M, Morishita N, Kawase I. Higashiguchi M, et al. Anticancer Res. 2012 Apr;32(4):1423-7. Anticancer Res. 2012. PMID: 22493380
58 results